Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions.

Endocannabinoid system Enzyme inhibitors Fatty acid amide hydrolase Neuroinflammation Neuroprotection Reversible inhibitors Selective inhibitors

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Jan 2023
Historique:
received: 14 10 2022
revised: 10 11 2022
accepted: 20 11 2022
pubmed: 4 12 2022
medline: 4 1 2023
entrez: 3 12 2022
Statut: ppublish

Résumé

The neuroprotective performance against neuroinflammation of the endocannabinoid system (ECS) can be remarkably improved by indirect stimulation mediated by the pharmacological inhibition of the key ECS catabolic enzyme fatty acid amide hydrolase (FAAH). Based on our previous works and aiming to discover new selective FAAH inhibitors , we herein reported a new series of carbamate-based FAAH inhibitors (4a-t) which showed improved drug disposition properties compared to the previously reported analogues 2a-b. The introduction of ionizable functions allowed us to obtain new FAAH inhibitors of nanomolar potency characterized by good water solubility and chemical stability at physiological pH. Interesting structure-activity relationships (SARs), deeply analyzed by molecular docking and molecular dynamic (MD) simulations, were obtained. All the newly developed inhibitors showed an excellent selectivity profile evaluated against monoacylglycerol lipase and cannabinoid receptors. The reversible mechanism of action was determined by a rapid dilution assay. Absence of toxicity was confirmed in mouse fibroblasts NIH3T3 (for compounds 4e, 4g, 4n-o, and 4s) and in human astrocytes cell line 1321N1 (for compounds 4e, 4n, and 4s). The absence of undesired cardiac effects was also confirmed for compound 4n. Selected analogues (compounds 4e, 4g, 4n, and 4s) were able to reduce oxidative stress in 1321N1 astrocytes and exhibited notable neuroprotective effects when tested in an ex vivo model of neuroinflammation.

Identifiants

pubmed: 36462439
pii: S0223-5234(22)00854-6
doi: 10.1016/j.ejmech.2022.114952
pii:
doi:

Substances chimiques

Enzyme Inhibitors 0
fatty-acid amide hydrolase EC 3.5.1.-
Amidohydrolases EC 3.5.-
Endocannabinoids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114952

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stefania Butini reports financial support was provided by Government of Italy Ministry of Education University and Research.

Auteurs

Alessandro Papa (A)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Silvia Pasquini (S)

Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Università degli Studi di Ferrara, Via Borsari 46, 44121, Ferrara, Italy.

Francesca Galvani (F)

Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, 43124, Parma, Italy.

Mariarosaria Cammarota (M)

Divisione di Farmacologia, Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli Studi di Napoli Federico II, Via Pansini 5, 80131, Napoli, Italy.

Chiara Contri (C)

Dipartimento di Medicina Traslazionale, Università degli Studi di Ferrara, Via Borsari 46, 44121, Ferrara, Italy.

Gabriele Carullo (G)

Dipartiment di Scienze della Vita, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Sandra Gemma (S)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Anna Ramunno (A)

Dipartimento di Farmacia, Università degli Studi di Salerno, Viale Giovanni Paolo II 132, 84084, Fisciano (SA), Italy.

Stefania Lamponi (S)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Beatrice Gorelli (B)

Dipartiment di Scienze della Vita, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Simona Saponara (S)

Dipartiment di Scienze della Vita, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Katia Varani (K)

Dipartimento di Medicina Traslazionale, Università degli Studi di Ferrara, Via Borsari 46, 44121, Ferrara, Italy.

Marco Mor (M)

Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, 43124, Parma, Italy; Microbiome Research Hub, Università degli Studi di Parma, Parco Area delle Scienze 11/A, I-43124, Parma, Italy.

Giuseppe Campiani (G)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Francesca Boscia (F)

Divisione di Farmacologia, Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli Studi di Napoli Federico II, Via Pansini 5, 80131, Napoli, Italy.

Fabrizio Vincenzi (F)

Dipartimento di Medicina Traslazionale, Università degli Studi di Ferrara, Via Borsari 46, 44121, Ferrara, Italy.

Alessio Lodola (A)

Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, 43124, Parma, Italy.

Stefania Butini (S)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy. Electronic address: butini3@unisi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH